<DOC>
	<DOCNO>NCT01570868</DOCNO>
	<brief_summary>The goal clinical research study learn ponatinib help control Chronic Myeloid Leukemia ( CML ) accelerate phase . The safety drug also study . Ponatinib design block function BCR-ABL , abnormal protein responsible cause leukemia certain cell . Ponatinib may cause blood clot form artery vein . Depending location clot , could cause heart attack , stroke , severe damage tissue , death . A blood clot may occur within 2 week start take drug . About 25 % ( 1 4 ) patient take drug form abnormal clot . Blood clot occur patient know risk factor form clot . If develop blood clot , need stop take ponatinib . In case , emergency surgery could need remove clot restore blood flow .</brief_summary>
	<brief_title>Ponatinib - Frontline Chronic Myeloid Leukemia ( CML ) Accelerated Phase ( AP )</brief_title>
	<detailed_description>Study Drug Administration : You take ponatinib mouth 1 time every day study cup ( 8 ounce ) water . You eat within 2 hour take drug . You complete study diary record date time take study drug time . If miss dos , also note study diary . Bring diary every study visit , describe . Study Visits : The test procedure study wide range time do . In general , schedule study visit follow : - Weekly Month 1 - Monthly Year 1 - Three ( 3 ) 4 time Year 2 - Two ( 2 ) 3 time every year The study staff help schedule study visit . The following test procedure perform : - Every 1-2 week first 4 week , every 4-6 week first year , every 3-4 month next year , every 4-6 month , blood ( 1/2 tablespoon ) drawn routine test . - Every 3 month first year , ECG . - Every 3 month first year , every 6-12 month , physical exam . - Every 3-4 month first year , every 6-12 month , blood ( 2 teaspoon ) draw measure level leukemia cell body . - Every 3-4 month first year , every 6-12 month next 2 year , every 2-3 year , bone marrow aspirate genetic test check status disease . Length Participation : You may continue take study drug 5 year . You take study early intolerable side effect occur , disease get bad , unable follow study direction . Your participation study complete follow-up visit/call . Follow-Up : If leave study , call come clinic within 30 day learn side effect symptom may . If call , call last 2-3 minute . This investigational study . Ponatinib FDA approve treat patient certain type leukemia . Its use study investigational . Up 80 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>1 . Diagnosis Phpositive ( cytogenetics FISH ) BcrABLpositive ( PCR ) CML accelerate phase feature time diagnosis . 2 . Patients must receive minimal prior therapy , define &lt; /=1 month prior IFNÎ± ( without araC ) and/or FDAapproved tyrosine kinase inhibitor ( e.g , dasatinib , nilotinib ) . Prior use hydroxyurea anagrelide allow limitation . 3 . Age &gt; /=18 year 4 . Eastern Cooperative Oncology Group ( ECOG ) performance 02 . 5 . Adequate end organ function , define follow : total bilirubin &lt; 1.5x upper limit normal ( ULN ) , serum glutamate pyruvate transaminase ( SGPT ) &lt; 2.5x ULN , creatinine clearance ( CrCl ) &gt; /= 30 mL/min screening ( calculation accord Cockcroft &amp; Gault formula ) . 6 . Patients must sign informed consent indicate aware investigational nature study , keep policy hospital . 7 . Women pregnancy potential must practice effective method birth control course study , manner risk failure minimize . Prior study enrollment , woman childbearing potential ( WOCBP ) must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy . Postmenopausal woman must amenorrheic least 12 month consider nonchildbearing potential . In addition , men enrol study understand risk sexual partner childbearing potential practice effective method birth control . Adequate form contraception barrier method ( e.g. , condom , diaphragm ) , oral , depo provera , injectable contraceptive , intrauterine device , spermicidal jelly foam , abstinence , tubal ligation . Women men must continue birth control duration trial &amp; least 3 month last dose study drug . 8 . **continued : All WOCBP MUST negative serum urine pregnancy test within 7 day prior first receive investigational product . If pregnancy test positive , patient must receive investigational product must enrol study . 1 . NYHA cardiac class 34 heart disease 2 . Cardiac Symptoms : Patients meet follow criterion eligible : History unstable angina , myocardial infarction , transient ischemic attack ( TIA ) , stroke , peripheral arterial occlusive disease , venous thromboembolism pulmonary embolism ; Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) ; Prolonged correct QT interval ( QTc ) interval preentry electrocardiogram ( &gt; 470 msec ) Fridericia Bazett 's correction ; Symptomatic congestive heart failure within 3 month prior first dose ponatinib ( NYHA class III IV ) . 3 . Patients active , uncontrolled psychiatric disorder include : psychosis , major depression , bipolar disorder . 4 . Pregnant breastfeed woman exclude . 5 . Patients uncontrolled hypertension ( define sustain stage 2 hypertension , i.e. , systolic BP &gt; /=160 mmHg diastolic BP &gt; /=100 mmHg ) . 6 . Patients history pancreatitis . 7 . Patients late chronic phase ( i.e. , time diagnosis treatment &gt; 6 month ) , blast phase exclude . The definition CML phase follow : A . Early chronic phase : time diagnosis therapy &lt; /= 6 month ; B . Late chronic phase : time diagnosis therapy &gt; 6 month ; C. Blastic phase : presence 30 % blast peripheral blood bone marrow ; D. Accelerated phase CML : presence follow feature : Peripheral marrow blast 15 % ; Peripheral marrow basophils 20 % ; Thrombocytopenia &lt; 100 x 10 ( 9 ) /L unrelated therapy ; Documented extramedullary blastic disease outside liver spleen . 8 . **continued : E. Clonal evolution define presence additional chromosomal abnormality Ph chromosome historically include criterion accelerate phase . However , patient clonal evolution criterion accelerate phase significantly well prognosis , present diagnosis may impact prognosis . Thus , patient clonal evolution criterion accelerate phase eligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Chronic Phase</keyword>
	<keyword>Cytogenetic response</keyword>
	<keyword>CCyR</keyword>
	<keyword>Major molecular response</keyword>
	<keyword>MMR</keyword>
	<keyword>Complete molecular response</keyword>
	<keyword>CMR</keyword>
	<keyword>Ponatinib</keyword>
	<keyword>AP24534</keyword>
</DOC>